Literature DB >> 9673741

Commercial detailing techniques used by pharmaceutical representatives to influence prescribing.

E E Roughead1, K J Harvey, A L Gilbert.   

Abstract

AIM: To determine the use of influence techniques by pharmaceutical representatives in their encounters with medical practitioners.
METHOD: We identified six influence techniques from the marketing literature which are thought to be commonly used by sales people. These have been termed the principles of reciprocity, friendship/liking, commitment/consistency, social validation, authority, and scarcity. We examined the use of these techniques by analysing audio-recordings of pharmaceutical representatives' presentations to medical practitioners.
RESULTS: Sixteen recordings, detailing 64 medicines, were obtained from seven medical practitioners. Reciprocation was the most commonly observed method of influence. Samples, gifts, printed material, patient information leaflets or invitations were offered in all encounters. Appeals to authority figures, where promotional claims were supported by reference to professors or specialists, specialist groups and specialist hospitals, were recorded. Social validation acts, where reference was made to the peer group were also common. Commitment acts were observed to occur in two ways; the first was as a direct request to use the product detailed and the second was as a series of questions or statements which gradually moved from pre-agreed areas to solicitation of a commitment to prescribe the drug.
CONCLUSION: Influence techniques were found to be commonly used by pharmaceutical representatives when they detailed products to medical practitioners. Medical practitioners may not be aware of the potential effect these techniques can have on their prescribing practices. Knowledge of these techniques must be incorporated into educational programmes designed to provide health professionals with critical appraisal skills.

Entities:  

Keywords:  Bioethics and Professional Ethics; Empirical Approach

Mesh:

Year:  1998        PMID: 9673741     DOI: 10.1111/j.1445-5994.1998.tb01953.x

Source DB:  PubMed          Journal:  Aust N Z J Med        ISSN: 0004-8291


  7 in total

1.  Dramaturgical study of meetings between general practitioners and representatives of pharmaceutical companies; Commentary: dramaturgical model gives valuable insight.

Authors:  M Somerset; M Weiss; T Fahey
Journal:  BMJ       Date:  2001 Dec 22-29

2.  General practitioners' adoption of new drugs and previous prescribing of drugs belonging to the same therapeutic class: a pharmacoepidemiological study.

Authors:  Torben Dybdahl; Morten Andersen; Jakob Kragstrup; Ivar Sønbø Kristiansen; Jens Søndergaard
Journal:  Br J Clin Pharmacol       Date:  2005-11       Impact factor: 4.335

3.  Results of a 12-month quality-circle prescribing improvement programme for GPs.

Authors:  Françoise Riou; Christine Piette; Gérard Durand; Jacques Chaperon
Journal:  Br J Gen Pract       Date:  2007-07       Impact factor: 5.386

4.  GPs' attitudes to benzodiazepine and 'Z-drug' prescribing: a barrier to implementation of evidence and guidance on hypnotics.

Authors:  A Niroshan Siriwardena; Zubair Qureshi; Steve Gibson; Sarah Collier; Martin Latham
Journal:  Br J Gen Pract       Date:  2006-12       Impact factor: 5.386

Review 5.  Legislative, educational, policy and other interventions targeting physicians' interaction with pharmaceutical companies: a systematic review.

Authors:  Lina Alkhaled; Lara Kahale; Hala Nass; Hneine Brax; Racha Fadlallah; Kamal Badr; Elie A Akl
Journal:  BMJ Open       Date:  2014-07-01       Impact factor: 2.692

6.  A survey of pharmaceutical company representative interactions with doctors in Libya.

Authors:  Mustafa A Alssageer; Stefan R Kowalski
Journal:  Libyan J Med       Date:  2012-09-18       Impact factor: 1.657

7.  Characteristics and impact of drug detailing for gabapentin.

Authors:  Michael A Steinman; G Michael Harper; Mary-Margaret Chren; C Seth Landefeld; Lisa A Bero
Journal:  PLoS Med       Date:  2007-04       Impact factor: 11.069

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.